Evotec AG is a drug discovery and development company. The Company operates through two segments. The EVT Execute segment provides standalone drug discover services on a typical fee-for-service basis or integrated drug discovery collaborations on partners' target through a range of commercial structures, including research fees, milestones and/or royalties. The EVT Innovate segment develops drug discovery programs and assets, both internally or through academic collaborations. The Company seeks to partner these into collaborations in return for upfront payments, ongoing research payments. It consists of all partnerships derived from its internally developed assets and platforms and its participations in certain companies. It includes clinical initiations and progress of clinical pipeline within partnerships; expansion of academic BRIDGE network; research and development (R&D) progress with CureX/Target X initiatives, and focuses on induced pluripotent stem cells (iPSC) platform.

Pharmaceutical

Evotec

Craig Johnstone

Laetitia Rouxel

Cord Dohrmann

Hans-Ulrich Wolf

The Business Development team at Evotec focuses on identifying and establishing strategic partnerships and collaborations to support the company's drug discovery and development efforts. This team works on negotiating and securing research fees, milestones, and royalties, as well as managing relationships with academic institutions and industry partners. They also play a crucial role in expanding Evotec's market presence and driving growth by leveraging both the EVT Execute and EVT Innovate segments for commercial success.

Business Development

Scientific Research & Development

Vice Presidents and Senior Vice Presidents

Project and Operations Management

Business Development

About

Team members

Other teams at Evotec

Scientific Research & Development

Vice Presidents and Senior Vice Presidents

Project and Operations Management